On the cusp of a cash crunch that could have threatened its survival, MannKind Corporation (NASDAQ: MNKD) secured $45 million in upfront cash from United Therapeutics (NASDAQ: UTHR) this week to develop an inhaled version of Remodulin, a top-selling drug for pulmonary arterial hypertension that's losing patent exclusivity this year. The cash, plus an additional $10 million for an undisclosed drug development program, gives MannKind more time to grow sales of its inhaled insulin, Afrezza, but MannKind isn't out of the woods yet. It's still burning through cash, and that could cause problems for investors in 2019. In this episode of The Motley Fool's Industry Focus: Healthcare, host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to dig into the details of this deal and its impact on bulls and bears.